To investigate whether our newly identified anti-myeloma antibodies may have therapeutic potential, the VH and VL sequences of scFv phage antibody #5 were used to generate a chimeric CD38 IgG1 antibody for comparison with the clinically approved CD38 IgG1 antibodies daratumumab and isatuximab in first proof-of-concept studies. This evidence concerns the gene CD38 and plasma cell myeloma.